Chemed Corp. (NYSE:CHE) Director Patrick P. Grace sold 400 shares of the business’s stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $148.53, for a total transaction of $59,412.00. Following the sale, the director now owns 4,597 shares in the company, valued at $682,792.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Chemed Corp. (NYSE:CHE) opened at 150.03 on Wednesday. The stock’s 50 day moving average price is $141.89 and its 200-day moving average price is $138.01. Chemed Corp. has a 12 month low of $124.77 and a 12 month high of $159.76. The firm has a market capitalization of $2.43 billion, a P/E ratio of 23.95 and a beta of 1.25.

Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Wednesday, October 26th. The company reported $1.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.82 by $0.09. Chemed Corp. had a return on equity of 23.95% and a net margin of 6.77%. The business earned $392.61 million during the quarter, compared to analyst estimates of $270.44 million. During the same period in the previous year, the business posted $1.78 earnings per share. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. On average, analysts forecast that Chemed Corp. will post $7.24 earnings per share for the current year.

Insider Buying and Selling by Quarter for Chemed Corp. (NYSE:CHE)

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Monday, November 14th will be paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Wednesday, November 9th. Chemed Corp.’s payout ratio is 16.59%.

COPYRIGHT VIOLATION WARNING: “Patrick P. Grace Sells 400 Shares of Chemed Corp. (CHE) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/30/patrick-p-grace-sells-400-shares-of-chemed-corp-che-stock.html.

A number of hedge funds have recently modified their holdings of the company. Emerald Acquisition Ltd. acquired a new stake in shares of Chemed Corp. during the second quarter worth about $26,177,000. Fiera Capital Corp acquired a new stake in shares of Chemed Corp. during the second quarter worth about $17,291,000. BlackRock Fund Advisors raised its stake in shares of Chemed Corp. by 6.2% in the third quarter. BlackRock Fund Advisors now owns 1,109,056 shares of the company’s stock worth $156,455,000 after buying an additional 64,981 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Chemed Corp. by 3.1% in the second quarter. Vanguard Group Inc. now owns 1,576,155 shares of the company’s stock worth $214,846,000 after buying an additional 46,726 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Chemed Corp. during the second quarter worth about $5,483,000. 97.40% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the stock. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $155.00 price target on shares of Chemed Corp. in a research note on Tuesday, September 27th. Zacks Investment Research lowered shares of Chemed Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, November 1st. JMP Securities reiterated a “hold” rating on shares of Chemed Corp. in a research note on Sunday, September 4th. Royal Bank Of Canada cut their price target on shares of Chemed Corp. from $162.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 1st. Finally, RBC Capital Markets reiterated a “sector perform” rating and set a $148.00 price target (down from $162.00) on shares of Chemed Corp. in a research note on Tuesday, November 1st. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $154.50.

About Chemed Corp.

Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

5 Day Chart for NYSE:CHE

Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.